Latest Product News
Personalis and Moderna Sign New Agreement To Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
The platform will be used to sequence genomic information from a patient’s tumor sample to identify the unique genetic mutations that are most likely to generate a tailored antitumor response.
Avacta Announces Successful Completion of Fourth Dose Escalation in Phase 1 Clinical Study
Avacta Group plc announces that AVA6000 continues to show a very favorable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial.
Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers Into ColoAlert
Mainz Biomed NV has announced the first patient has been enrolled in eAArly DETECT, Mainz’s U.S. extension of ColoFuture, its European feasibility study evaluating the integration of a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert.
Cell-Permeable Small Molecules for Regenerative Medicine and Cancer Research
AMSBIO offers a wide range of small molecules to provide scientists with targeted tools to direct cell fates, making them crucial in areas including regenerative medicine and cancer research.
Mainz Biomed Announce IRB Approval and Initiation of US Pivotal FDA Clinical Study
Mainz Biomed has received approval from an independent Institutional Review Board for the protocol ReconAAsense, the Company’s US pivotal study to evaluate the clinical performance of its highly efficacious and easy-to-use detection test for colorectal cancer.
New dPCR Liquid Biopsy Assays for QuantStudio Absolute Q dPCR System and Custom Design Tool Simplify Cancer Research
Thermo Fisher Scientific has introduced over 50 new Absolute Q Liquid Biopsy Assays to run on the Applied Biosystems QuantStudio Absolute Q dPCR System.
Personalis and UCSF To Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
Personalis has announced a collaboration with UC San Francisco that will deploy a personalized liquid biopsy-based research use only assay for a study of patients with colorectal cancer.
Nautilus Biotechnology Launches “First Access Challenge”
Open competition allows researchers to be among the first to access potentially groundbreaking proteomic data through the testing of twelve samples on Nautilus’ single-molecule protein analysis platform.
Mainz Biomed Announces US Extension of ColoFuture Study To Evaluate Integration of Novel mRNA Biomarkers Into ColoAlert
Mainz Biomed has announced the initiation of eAArly DETECT, its US extension of ColoFuture, which is the Company’s European feasibility study evaluating the integration of a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert.
Actym Therapeutics Reports Preclinical Data Demonstrating ACTM-838’s Ability To Generate Anti-Tumor Immunity
Actym Therapeutics has announced that an abstract highlighting detailed preclinical data of its lead candidate, ACTM-838, was accepted for presentation at the Society for Immunotherapy of Cancer 37th Annual Meeting.